Connection

Michael Gold to Heart Failure

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Heart Failure.
Michael Gold
Connection Strength
16.107
Heart Failure
  1. Association of left ventricular remodeling with cardiac resynchronization therapy outcomes. Heart Rhythm. 2023 02; 20(2):173-180.
    View in: PubMed
    Score: 0.435
  2. Association of interventricular activation delay with clinical outcomes in cardiac resynchronization therapy. Heart Rhythm. 2023 Mar; 20(3):385-392.
    View in: PubMed
    Score: 0.435
  3. Role of Electrical Delay in Cardiac Resynchronization Therapy Response. Card Electrophysiol Clin. 2022 06; 14(2):233-241.
    View in: PubMed
    Score: 0.420
  4. CRT Efficacy in "Mid-Range" QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height. JACC Clin Electrophysiol. 2022 02; 8(2):211-221.
    View in: PubMed
    Score: 0.405
  5. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.402
  6. Electrical delays in quadripolar leads with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2021 09; 32(9):2498-2503.
    View in: PubMed
    Score: 0.396
  7. Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2021 07; 7(7):871-880.
    View in: PubMed
    Score: 0.385
  8. The ECG Belt for CRT response trial: Design and clinical protocol. Pacing Clin Electrophysiol. 2020 10; 43(10):1063-1071.
    View in: PubMed
    Score: 0.372
  9. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
    View in: PubMed
    Score: 0.360
  10. The rationale and design of the SMART CRT trial. Pacing Clin Electrophysiol. 2018 09; 41(9):1212-1216.
    View in: PubMed
    Score: 0.323
  11. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
    View in: PubMed
    Score: 0.322
  12. Computer Modeling: The Future of Cardiac Resynchronization Therapy Patient Selection? Circ Arrhythm Electrophysiol. 2018 01; 11(1):e006104.
    View in: PubMed
    Score: 0.309
  13. The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
    View in: PubMed
    Score: 0.308
  14. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
    View in: PubMed
    Score: 0.296
  15. Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
    View in: PubMed
    Score: 0.295
  16. ICD Utilization: Can We Select the Right Patients? JACC Clin Electrophysiol. 2017 03; 3(3):299-301.
    View in: PubMed
    Score: 0.293
  17. Economic Value and Cost-Effectiveness of?Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 03; 5(3):204-212.
    View in: PubMed
    Score: 0.289
  18. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Fail Clin. 2017 Jan; 13(1):209-223.
    View in: PubMed
    Score: 0.289
  19. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.278
  20. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
    View in: PubMed
    Score: 0.274
  21. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Card Electrophysiol Clin. 2015 Dec; 7(4):765-79.
    View in: PubMed
    Score: 0.268
  22. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
    View in: PubMed
    Score: 0.262
  23. Expanding the boundaries of heart failure care with interventional and device therapy. Heart Fail Clin. 2015 Apr; 11(2):xiii.
    View in: PubMed
    Score: 0.254
  24. Vagal nerve stimulation for heart failure: new pieces to the puzzle? Eur J Heart Fail. 2015 Feb; 17(2):125-7.
    View in: PubMed
    Score: 0.253
  25. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.249
  26. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
    View in: PubMed
    Score: 0.236
  27. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.231
  28. How many transvenous coils are optimal for defibrillators: one, two, or none? Heart Rhythm. 2013 Jul; 10(7):977-8.
    View in: PubMed
    Score: 0.224
  29. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
    View in: PubMed
    Score: 0.222
  30. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.212
  31. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.212
  32. Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012 Jan; 23(1):110-8.
    View in: PubMed
    Score: 0.204
  33. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.199
  34. Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy. Heart Fail Clin. 2011 Apr; 7(2):241-50, ix.
    View in: PubMed
    Score: 0.194
  35. Cardiac resynchronization therapy for mild heart failure: the time has come. Circulation. 2011 Jan 18; 123(2):195-202.
    View in: PubMed
    Score: 0.191
  36. A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
    View in: PubMed
    Score: 0.190
  37. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
    View in: PubMed
    Score: 0.190
  38. Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials. Curr Cardiol Rep. 2010 Sep; 12(5):367-73.
    View in: PubMed
    Score: 0.186
  39. Response to Coceani: Has CRT earned a class I recommendation? Circ Heart Fail. 2010 Jul; 3(4):559-60.
    View in: PubMed
    Score: 0.184
  40. Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
    View in: PubMed
    Score: 0.168
  41. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
    View in: PubMed
    Score: 0.168
  42. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
    View in: PubMed
    Score: 0.164
  43. Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
    View in: PubMed
    Score: 0.147
  44. Myocardial contractile reserve as a predictor of cardiac resynchronization therapy response. Heart Rhythm. 2006 Apr; 3(4):414-5.
    View in: PubMed
    Score: 0.136
  45. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
    View in: PubMed
    Score: 0.128
  46. Iatrogenic ventricular dyssynchrony: a preventable cause of heart failure with right ventricular pacing? Heart Rhythm. 2005 Mar; 2(3):252-3.
    View in: PubMed
    Score: 0.127
  47. Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. Clin Cardiol. 2004 Mar; 27(3):151-3.
    View in: PubMed
    Score: 0.119
  48. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
    View in: PubMed
    Score: 0.110
  49. Long-term outcomes in nonprogressors to cardiac resynchronization therapy. Heart Rhythm. 2023 02; 20(2):165-170.
    View in: PubMed
    Score: 0.108
  50. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
    View in: PubMed
    Score: 0.107
  51. The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studies. Heart Rhythm. 2022 04; 19(4):595-603.
    View in: PubMed
    Score: 0.101
  52. Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart?Failure Status. JACC Clin Electrophysiol. 2022 02; 8(2):182-193.
    View in: PubMed
    Score: 0.101
  53. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.096
  54. Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial. Am Heart J. 2021 05; 235:158-162.
    View in: PubMed
    Score: 0.096
  55. Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. J Med Econ. 2020 Dec; 23(12):1401-1408.
    View in: PubMed
    Score: 0.094
  56. Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. J Cardiovasc Electrophysiol. 2020 12; 31(12):3166-3175.
    View in: PubMed
    Score: 0.094
  57. Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Fail. 2020 10; 7(5):2972-2982.
    View in: PubMed
    Score: 0.093
  58. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000 May 01; 85(9):1106-9.
    View in: PubMed
    Score: 0.091
  59. Future research prioritization in cardiac resynchronization therapy. Am Heart J. 2020 05; 223:48-58.
    View in: PubMed
    Score: 0.090
  60. Pacing for patients with congestive heart failure and dilated cardiomyopathy. Cardiol Clin. 2000 Feb; 18(1):55-66.
    View in: PubMed
    Score: 0.089
  61. Left ventricular endocardial pacing: don't try this at home. Pacing Clin Electrophysiol. 1999 Nov; 22(11):1567-9.
    View in: PubMed
    Score: 0.088
  62. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.082
  63. Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk?of Heart Failure. J Am Coll Cardiol. 2018 06 12; 71(23):2603-2611.
    View in: PubMed
    Score: 0.080
  64. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
    View in: PubMed
    Score: 0.077
  65. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.076
  66. Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. Eur J Heart Fail. 2017 07; 19(7):950-957.
    View in: PubMed
    Score: 0.075
  67. The Impact of the PR Interval in Patients?Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2017 08; 3(8):818-826.
    View in: PubMed
    Score: 0.074
  68. Predictors of short-term clinical response to cardiac resynchronization therapy. Eur J Heart Fail. 2017 08; 19(8):1056-1063.
    View in: PubMed
    Score: 0.073
  69. The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997 Mar 01; 79(5):679-81.
    View in: PubMed
    Score: 0.073
  70. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.073
  71. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
    View in: PubMed
    Score: 0.071
  72. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol. 1995 Oct; 26(4):967-73.
    View in: PubMed
    Score: 0.066
  73. The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. Am J Cardiol. 2015 Oct 15; 116 Suppl 1:S1-9.
    View in: PubMed
    Score: 0.066
  74. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.066
  75. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.066
  76. Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
    View in: PubMed
    Score: 0.066
  77. Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol. 1995 Jun 01; 75(16):1158-61.
    View in: PubMed
    Score: 0.065
  78. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
    View in: PubMed
    Score: 0.064
  79. The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
    View in: PubMed
    Score: 0.064
  80. Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
    View in: PubMed
    Score: 0.059
  81. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994 Mar 01; 23(3):560-4.
    View in: PubMed
    Score: 0.059
  82. Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
    View in: PubMed
    Score: 0.059
  83. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1236-44; discussion 1244-5.
    View in: PubMed
    Score: 0.058
  84. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.057
  85. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.057
  86. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
    View in: PubMed
    Score: 0.056
  87. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
    View in: PubMed
    Score: 0.053
  88. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
    View in: PubMed
    Score: 0.053
  89. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012 Jun; 163(6):954-962.e1.
    View in: PubMed
    Score: 0.053
  90. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
    View in: PubMed
    Score: 0.051
  91. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.050
  92. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.048
  93. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.047
  94. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.047
  95. Assessment of a novel device-based diagnostic algorithm to monitor patient status in moderate-to-severe heart failure: rationale and design of the CLEPSYDRA study. Eur J Heart Fail. 2010 Dec; 12(12):1363-71.
    View in: PubMed
    Score: 0.047
  96. SmartDelay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design. Pacing Clin Electrophysiol. 2010 Jan; 33(1):54-63.
    View in: PubMed
    Score: 0.044
  97. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.044
  98. Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009 Aug; 20(8):894-900.
    View in: PubMed
    Score: 0.042
  99. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
    View in: PubMed
    Score: 0.041
  100. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale. Am Heart J. 2007 Jan; 153(1):7-13.
    View in: PubMed
    Score: 0.036
  101. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.034
  102. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol. 2003 Nov; 14(11):1180-6.
    View in: PubMed
    Score: 0.029
  103. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.026
  104. Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1741-3.
    View in: PubMed
    Score: 0.024
  105. Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
    View in: PubMed
    Score: 0.024
  106. Optimization of ventricular pacing: where should we implant the leads? J Am Coll Cardiol. 1999 Feb; 33(2):324-6.
    View in: PubMed
    Score: 0.021
  107. Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. Am Heart J. 1995 Sep; 130(3 Pt 1):489-93.
    View in: PubMed
    Score: 0.016
  108. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
    View in: PubMed
    Score: 0.016
  109. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 Jul 01; 130(1):94-125.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.